

From Libby Circ 104:365,2001




PRECISION PRECISION






OA


RA



Interference with ASA Antiplatelet Effect





Dose-Dependent Pharmacodynamic Interaction



Catella-Lawson et al. NEJM 2001;345:1809


Li et al. PNAS 111: 16830, 2014

Variable NSAID Use, FU, + Ascertainment of Events




Relative Risk of Events

Drug Regimen A : Drug Regimen B




Dose-Related Increase in Risk with Celecoxib




CNT Meta-Analysis
Lancet 382: 769, 2013
Supplementary Material

≡

Interaction of Celecoxib Dose and Baseline CV Risk



Solomon
Circ 117:2104, 2008



- **Lowest Risk Patient**
- **Lowest Risk Drug**
- **Lowest Dose Needed**
- **Shortest Period of Time**




American Heart Association
Circulation
115:1634, 2007






EUROPEAN SOCIETY OF CARDIOLOGY
EHJ-CV Pharm
2:108, 2016

**Current Approach:
Common Phenotype
Average Response**



Precision Medicine Approach



**Urgent Clinical Need:
Novel Analgesics and
Other Therapeutics to
Avoid CV Risk from all NSAIDs**